AEON Biopharma Future Growth
Future criteria checks 0/6
AEON Biopharma is forecast to grow revenue at 99.1% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 28.5% |
| Revenue growth rate | 99.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 14 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | N/A | N/A | N/A | 1 |
| 12/31/2025 | N/A | N/A | N/A | N/A | 1 |
| 12/31/2024 | N/A | N/A | N/A | N/A | 1 |
| 9/30/2024 | N/A | 14 | -31 | -31 | N/A |
| 6/30/2024 | N/A | -306 | -43 | -43 | N/A |
| 3/31/2024 | N/A | -137 | -45 | -45 | N/A |
| 12/31/2023 | N/A | -385 | -48 | -48 | N/A |
| 9/30/2023 | N/A | -393 | -45 | -45 | N/A |
| 6/30/2023 | N/A | -78 | -41 | -41 | N/A |
| 3/31/2023 | N/A | -66 | -39 | -39 | N/A |
| 12/31/2022 | N/A | -53 | -36 | -36 | N/A |
| 9/30/2022 | N/A | -25 | -35 | -35 | N/A |
| 6/30/2022 | N/A | -27 | -30 | -30 | N/A |
| 3/31/2022 | N/A | -61 | -28 | -28 | N/A |
| 12/31/2021 | N/A | -56 | -29 | -28 | N/A |
| 9/30/2021 | 1 | -58 | -23 | -23 | N/A |
| 6/30/2021 | 1 | -54 | -20 | -20 | N/A |
| 3/31/2021 | 2 | -17 | -15 | -15 | N/A |
| 12/31/2020 | 3 | -50 | -9 | -9 | N/A |
| 12/31/2019 | 3 | 137 | -46 | -45 | N/A |
| 12/31/2018 | 2 | -101 | -40 | -40 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if AEON's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if AEON's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if AEON's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AEON is forecast to have no revenue next year.
High Growth Revenue: AEON is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AEON's Return on Equity is forecast to be high in 3 years time